Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Notes Payables: 2018-2025

  • China SXT Pharmaceuticals' Notes Payables rose 17.93% to $976,367 in Q3 2025 from the same period last year, while for Sep 2025 it was $976,367, marking a year-over-year increase of 17.93%. This contributed to the annual value of $702,184 for FY2025, which is 42.42% up from last year.
  • China SXT Pharmaceuticals' Notes Payables amounted to $976,367 in Q3 2025, which was up 39.05% from $702,184 recorded in Q1 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Notes Payables peaked at $976,367 during Q3 2025, and registered a low of $24,042 during Q3 2021.
  • Moreover, its 3-year median value for Notes Payables was $597,619 (2024), whereas its average is $572,374.
  • Its Notes Payables has fluctuated over the past 5 years, first plummeted by 47.46% in 2021, then surged by 209.77% in 2024.
  • Quarterly analysis of 4 years shows China SXT Pharmaceuticals' Notes Payables stood at $24,042 in 2021, then reached $267,270 in 2023, then spiked by 209.77% to $827,918 in 2024, then rose by 17.93% to $976,367 in 2025.
  • Its last three reported values are $976,367 in Q3 2025, $702,184 for Q1 2025, and $827,918 during Q3 2024.